Norman Weiner Lecture
Washington Convention Center, Room 143 A/B
8:30 am - 9:20 am
Robert J. Lefkowitz, Duke Univ. and HHMI
Seven Transmembrane Receptors: Something Old, Something New
New Roles for Arrestins in Signaling, Trafficking and Disease
Washington Convention Center, Room 143A/B
9:30 am – 12:00 noon
Sponsored by the Divisions for Molecular Pharmacology and Integrative Systems, Translational & Clinical Pharmacology
Chair: J.L. Benovic, Thomas Jefferson Univ.
Mechanistic insight into
arrestin-mediated trafficking
Jeffrey L. Benovic, Thomas Jefferson University
Behavioral selectivity of
arrestin-dependent dopamine mediated signaling
Marc
G. Caron, Duke
University Medical Center
Beta-arrestin1 signaling and
auto-immunity
Gang Pei, Shanghai
Institutes for Biological Sciences
Arrestin-related ubiquitin-ligase
adaptors required for endocytosis and PM protein down-regulation
Scott Emr, Cornell
University Weill Institute for Cell and Molecular Biology
Retromer terminates the generation of cAMP by
internalized G-protein-coupled PTH receptors
Timothy N. Feinstein, Univ
of Pittsburgh
Novel insights into the role of arrestin-2 in endosomal
sorting of CXCR4
Rohit Malik, Loyola Univ
Chicago
Cardiovascular KCNQ (Kv7) Potassium Channels: Physiological Regulators and Targets for Therapeutic Intervention
Washington Convention Center, Room 140B
9:30 am – 12:00 noon
Sponsored by the Divisions for Cardiovascular Pharmacology; Drug Discovery, Development & Regulatory Affairs; Integrative Systems & Translational & Clinical Pharmacology; and Molecular Pharmacology
Chairs: K.L. Byron, Loyola Univ. Strich Sch. of Med. and D.L. Kunze, MetroHealth Med. Ctr
Expression and function of KCNQ genes in the vasculature
Iain Greenwood, St. George's University, London
Vascular KCNQ channels as physiological signal transducers and novel targets for treatment of cardiovascular diseases
Kenneth L. Byron, Loyola University of Chicago, Stritch School of Medicine
KCNQ channels as a therapeutic target in pulmonary hypertension
Alison Gurney, University of Manchester, UK
KCNQ channels in the reflex regulation of arterial pressure
Diana L. Kunze, MetroHealth Medical Center
M channels in regulation of
cardiomyocyte contraction and in neuroprotection during stroke
Mark Shapiro, University of Texas HSC, San Antonio
Elucidating new mechanisms in vasoconstrictor signal transduction: Inhibition of Kv7.5 channel activity by PKCα
Valerie Hummert, Loyola Univ Chicago
Chronobiology in the Modern Curriculum - Addressing Disease Linkage and Pharmacological Approaches
Washington Convention Center, Room 143C
9:30 am – 12:00 noon
Sponsored by the Divisions for Neuropharmacology and Pharmacology Education; Behavioral Pharmacology and Integrative Systems,Translational & Clinical Pharmacology
Chair: M.W. Wood, AstraZeneca Pharmaceuticals and S. Tischkau, Southern Illinois Univ.
An overview of Circadian clock dysfunction and disease
Shelley A. Tischkau, Southern Illinois Univ School of Medicine
Pharmacological approaches to the treatment of sleep and wake disorders
John Renger, Merck Research Laboratories
Translational applications of biological rhythm research: clinical
chronobiology and chronotherapeutics
Michael H. Smolensky, Univ. of Texas Hlth. Sci. Ctr. at Houston
In cancer, as in all else: timing is everything
William J. Hrushesky, Dorn Veterans
Affairs Medical Center
Pharmacogenomics and Personalized Medicine
Washington Convention Center, 140A
9:30 am – 12:00 noon
Sponsored by the Divisions for Integrative Systems, Translational & Clinical Pharmacology; Drug Discovery, Development & Regulatory Affairs; Drug Metabolism; and Toxicology
Chair: A. Gaedigk, Children’s Mercy Hospitals and Clinics
Pharmacogenetics to pharmacogenomics
Richard Weinshilboum, Mayo Clinic College of Medicine
Pharmacogenetics and personalized medicine: Facing the challenges of bridging the gap between science and utility
Darrell Abernethy, FDA
From clinical utility to clinical effectiveness: A real world perspective on pharmacogenetics in clinical practice
Eric Stanek, Medco Health Solutions, Inc.
Incorporating pharmacogenetics into drug development
William Macias, Eli Lilly and Co.